Xolair

Three darts hitting bullseye
Biotech

Celldex monoclonal antibody rebounds with pair of phase 3 wins

The trials met both primary and secondary endpoints, giving Celldex’s barzolvolimab a chance at redemption after its recent phase 2 flop.
Marissa Russo Sep 22, 2026 10:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Cue chalks up phase 2 hives win for Xolair challenger

Sep 21, 2026 4:50am
NVS

Novartis pens $2B deal for biotech with potential Xolair successor

Mar 27, 2026 4:46am
GSK ESMO

GSK pays $2.2B to buy Rapt for food allergy challenger to Xolair

Jan 20, 2026 4:37am
Honeybees on honeycomb in hive

Novartis hands over $55M to license preclinical hives prospect

Mar 3, 2025 5:05pm
compass map direction find trail north

Rapt pays $35M for challenger to Novartis, Roche drug

Dec 23, 2024 8:10am